ENTRY       D05032                      Drug
NAME        Miglustat (JAN/USAN/INN);
            Brazaves (TN);
            Zavesca (TN)
PRODUCT     OPFOLDA (AMICUS THERAPEUTICS US)
            ZAVESCA (Actelion Pharmaceuticals US)
  GENERIC   MIGLUSTAT (ANI Pharmaceuticals)
            MIGLUSTAT (CoTherix)
            MIGLUSTAT (Edenbridge Pharmaceuticals LLC.)
            YARGESA (Edenbridge Pharmaceuticals LLC.)
FORMULA     C10H21NO4
EXACT_MASS  219.1471
MOL_WEIGHT  219.278
REMARK      Therapeutic category: 3999
            ATC code: A16AX06
            Product: D05032<JP/US>
EFFICACY    Lysosomal storage disease treatment, Glucosylceramide synthase inhibitor
  DISEASE   Type 1 Gaucher disease [DS:H00126]
            Pompe disease [DS:H01940]
TARGET      UGCG [HSA:7357] [KO:K00720]
  PATHWAY   hsa00600(7357)  Sphingolipid metabolism
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
               A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
                A16AX Various alimentary tract and metabolism products
                 A16AX06 Miglustat
                  D05032  Miglustat (JAN/USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
              Miglustat
               D05032  Miglustat (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D05032  Miglustat (JAN/USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Transferases (EC2)
               Hexosyltransferases
                UGCG
                 D05032  Miglustat (JAN/USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D05032
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D05032
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D05032
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D05032
            Pharmacogenomic biomarkers [br08341.html]
             Germline mutations in genetic disorder treatments
              D05032
DBLINKS     CAS: 72599-27-0
            PubChem: 47206759
            ChEBI: 50381
            PDB-CCD: NBV
            LigandBox: D05032
            NIKKAJI: J258.518I
ATOM        15
            1   C1y C    33.6700  -19.1800
            2   C1y C    33.6700  -20.5800
            3   C1y C    34.8824  -21.2800
            4   C1y C    36.0949  -20.5800
            5   C1x C    36.0949  -19.1800
            6   N1y N    34.8824  -18.4800
            7   O1a O    37.3260  -21.2910
            8   O1a O    32.4576  -21.2800
            9   O1a O    34.8824  -22.6798
            10  C1b C    32.4576  -18.4800
            11  C1b C    34.8824  -17.0802
            12  C1b C    36.0780  -16.3898
            13  C1b C    37.2652  -17.0752
            14  C1a C    38.4566  -16.3872
            15  O1a O    31.2621  -19.1704
BOND        15
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     5   6 1
            6     1   6 1
            7     4   7 1 #Down
            8     2   8 1 #Down
            9     3   9 1 #Up
            10    1  10 1 #Up
            11    6  11 1
            12   11  12 1
            13   12  13 1
            14   13  14 1
            15   10  15 1
///
